Literature DB >> 21770987

Computed tomography or magnetic resonance imaging-assisted partial hoof wall resection for keratoma removal.

Liberty M Getman1, Elizabeth J Davidson, Michael W Ross, Midge Leitch, Dean W Richardson.   

Abstract

OBJECTIVES: To (1) describe the computed tomography (CT) and magnetic resonance imaging (MRI) appearance of keratomas; (2) describe a CT- or MRI-assisted partial hoof wall resection technique for removal of keratomas; and (3) evaluate the morbidity and postoperative outcome of these horses. STUDY
DESIGN: Case series. ANIMALS: Horses (n=10) with keratoma.
METHODS: Data retrieved from medical records included signalment, lameness duration and grade, physical and diagnostic evaluation findings, CT and MRI technique and findings, surgical details, histopathologic diagnosis, postoperative treatment, and complications experienced. Long-term outcome was obtained by telephone interviews of owners.
RESULTS: Complications including excessive granulation tissue formation and infection were seen in 2 horses (20%). No keratoma recurrence occurred. Follow-up information was available for 8 horses; 7 were sound and had resumed work. Mean time until they became sound was 2.7 months, and mean time until work resumed was 3.6 months.
CONCLUSIONS: CT and MRI can be used to accurately identify the location of keratomas. Postoperative complications may be decreased by creating smaller hoof wall defects, filling the defects with antimicrobial-impregnated polymethylmethacrylate, and placing a shoe early in the postoperative period. © Copyright 2011 by The American College of Veterinary Surgeons.

Entities:  

Mesh:

Year:  2011        PMID: 21770987     DOI: 10.1111/j.1532-950X.2011.00864.x

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  1 in total

1.  Laminar epidermal hyperplasia and hyperkeratosis in an equine hoof.

Authors:  Dane M Tatarniuk; Joe L Bracamonte; David G Wilson; Ajay Sharma; Al W Perry
Journal:  Can Vet J       Date:  2013-09       Impact factor: 1.008

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.